It was a pleasure to speak with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis.
The abstract entitled ‘Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial’ was presented at AAD VMX, 23-25 April 2021.
- What is the rationale for the use of abrocitinib in the treatment of adults with moderate to severe atopic dermatitis? (0:14)
- Could you tell us about the unique design of the JADE REGIMEN Phase 3 study? (0:55)
- What was the response to abrocitinib in the induction, maintenance and rescue periods? (3:09)
- What was the safety profile of abrocitinib, and how can adverse events be minimized? (4:52)
- What are the significance of these findings in terms of the evolving treatment paradigm for atopic dermatitis? (6:18)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Brian Kim, EADV 2021: Difelikefalin for Pruritus in Atopic Dermatitis
It was a pleasure to meet up with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) to talk about the use of difelikefalin in treating pruritus associated with atopic dermatitis (AD). His presentation entitled ‘Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis’ was given at the EADV 30th Congress, 29 Sep – […]
Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis. His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in […]
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!